Temedica, a Munich, Germany-based well being insights firm, raised €25M in Sequence B funding.
The spherical, which introduced complete funding raised to this point to €42m, was led by MIG Capital, in addition to a Munich-based household workplace.
The corporate intends to make use of the funds to speed up enlargement of its ecosystem, which gives holistic insights into the care realities and affected person journeys of tens of millions of sufferers by combining health-related knowledge, and its improvement efforts.
Led by CEO and Founder Gloria Seibert, Temedica is a well being insights firm whose mission is to allow personalised and individualized drugs, thereby specializing in sufferers and their particular person wants. The corporate achieves this by linking health-related knowledge from numerous sources, that are processed into insights in compliance with the GDPR.
From greater than 40 billion knowledge factors on over 50,000 diagnoses, Temedica derives health-related insights on points similar to illness development, therapy effectiveness, affected person journeys, and medicine adherence. The ecosystem brings collectively knowledge from all kinds of sources, similar to registry knowledge, gross sales knowledge of medically related merchandise, insurance coverage knowledge, affected person expertise knowledge, and – with specific affected person consent – patient-generated knowledge from affected person companion apps. The insights gained from the linked knowledge provide tangible added worth to all stakeholders within the healthcare system: sufferers, well being care professionals, clinics, analysis establishments, pharmaceutical and biotechnology corporations, and pharmacies.